Lantheus Holdings submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for MK-6240 (florquinitau F-18), an investigational next-generation positron emission tomography (PET) imaging agent targeting aggregated tau neurofibrillary tangles (NFTs) in adults with cognitive impairment being evaluated for Alzheimer's disease (AD). Granted FDA Fast Track designation, MK-6240 carries a Prescription Drug User Fee Act (PDUFA) target action date of August 13, 2026 — as of this writing, no FDA action has been announced.
If approved, MK-6240 will become only the second FDA-approved tau-specific PET radiotracer — entering a commercial landscape pioneered by Eli Lilly's Tauvid (flortaucipir F-18), which was approved in May 2020. Two pivotal Phase 3 studies met their co-primary sensitivity and specificity endpoints (announced April 30, 2025), and Lantheus filed the NDA in the third quarter of 2025. Crucially, MK-6240 was designed to reduce the "off-target" binding in the choroid plexus, basal ganglia, and meninges that complicates first-generation tau imaging — a major source of reader uncertainty in early-stage cognitive assessment and clinical memory evaluations, where subtle medial temporal signal must be reliably distinguished from non-specific background uptake.
For biopharma executives, neuroradiologists, health economists, and market access directors navigating the rollout of disease-modifying anti-amyloid monoclonal antibodies (mAbs) — such as Biogen/Eisai's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab), compared in our Leqembi vs Kisunla access guide — MK-6240 represents a potential anatomical stage-gate for precise disease staging and clinical patient selection. However, commercial uptake faces severe reimbursement friction: tau radiotracers are absent from retail pharmacy pricing (such as CMS NADAC) and operate under provider-administered hospital outpatient payment rules (OPPS). While CMS retired the restrictive beta-amyloid PET National Coverage Determination (NCD 220.6.20) in October 2023, no national Medicare coverage policy exists for tau PET, forcing imaging centers to navigate disparate local Medicare Administrative Contractor (MAC) policies, technical coding requirements, and complex prior authorizations. And any commercial launch now plays out against a changed corporate backdrop: Curium agreed to acquire Lantheus in an $8 billion deal announced August 3, 2026.
MK-6240 (Florquinitau F-18) Strategic Landscape
│
┌────────────────────────────────┼────────────────────────────────┐
│ │ │
[Radiotracer Profile] [Clinical Utility] [Reimbursement Landscape]
• Florquinitau F-18 (Lantheus) • In vivo Tau NFT Imaging • Provider-Administered (OPPS)
• Next-Gen Tau PET Radioligand • Reduces Off-Target Binding • Absent from Retail CMS NADAC
• Fast Track / PDUFA: Aug 2026 • Stratifies Kisunla/Leqembi • Amyloid NCD Retired Oct 2023
• F-18 Half-Life (110 mins) • Complements p-tau217 triage • No National Tau PET NCD
What is MK-6240 (florquinitau F-18) and how does it target tau pathology?
Alzheimer's disease neuropathology is defined by two hallmark proteinopathies: extracellular amyloid-beta ($A\beta$) plaques and intracellular hyperphosphorylated tau neurofibrillary tangles (NFTs). While amyloid deposition begins 15 to 20 years before clinical symptom onset and reaches a plateau early in the disease continuum, the propagation of tau tangles through the neocortex correlates directly with synaptic loss, neuronal apoptosis, brain atrophy, and clinical cognitive decline.
MK-6240 (florquinitau F-18, originally discovered by Merck & Co., developed by Cerveau Technologies, and acquired by Lantheus Holdings in 2023, with Enigma Biomedical USA supporting development) is a high-affinity, selective fluorinated small-molecule radiotracer designed specifically to bind paired helical filaments (PHF) of hyperphosphorylated tau:
- High Target Affinity & Binding Specificity: In preclinical and in vitro binding studies, MK-6240 demonstrated high affinity for phosphorylated tau deposits in AD brain tissue, with a binding pattern consistent with NFT-rich cortical regions and minimal binding in amyloid plaque-rich, NFT-poor areas.
- Selectivity Over Other Aggregates: The tracer showed no displaceable binding in subcortical or non-AD brain regions in early characterization studies — the basis for its utility in distinguishing Alzheimer's-type tau from other pathologies.
- Fluorine-18 Radiochemistry: Labeled with Fluorine-18 ($^{18}\text{F}$), MK-6240 has a radioactive decay half-life ($t_{1/2}$) of 109.8 minutes. This allows regional cyclotron synthesis, automated radiochemical synthesis, quality control testing, and unit-dose commercial distribution via nuclear pharmacy networks to hospital outpatient imaging suites within a same-day delivery radius.
MK-6240 vs Amyloid & Biomarker Cascade
│
┌────────────────────────────────┼────────────────────────────────┐
│ │ │
[Plasma Blood Biomarkers] [Amyloid-Beta PET Imaging] [Tau-PET NFT Imaging]
• High-throughput screening • Confirms presence of amyloid • Precise anatomical staging
• p-tau217 / %p-tau217 ratio • Tracers: Amyvid, Neuraceq • Tracers: MK-6240, Tauvid
• High NPV (>90%) for pathology • Triggers anti-amyloid mAbs • Direct link to clinical decline
The Neuropathology of Alzheimer's: Braak Staging and PET Correlation
Understanding the clinical utility of MK-6240 requires examining how tau pathology spreads anatomically through the human brain according to the classical neuropathological staging established by Heiko and Eva Braak:
Braak Neuropathological Staging of Tau
│
┌────────────────────────────────┼────────────────────────────────┐
│ │ │
[Braak Stages I–II] [Braak Stages III–IV] [Braak Stages V–VI]
• Transentorhinal / Entorhinal • Limbic / Hippocampus • Neocortical / Isocortical
• Asymptomatic or early memory • Mild Cognitive Impairment • Moderate-to-Severe AD Dementia
• Sub-threshold amyloid plaque • Optimal anti-amyloid window • Extensive synaptic destruction
• MK-6240 detects early signal • Spreads to lateral temporal • Broad cortical visual read (+)
- Braak Stages I–II (Transentorhinal Stage): Tau neurofibrillary tangles originate in the transentorhinal and entorhinal cortices. At this stage, individuals are often cognitively unimpaired. First-generation tracers often fail to differentiate this subtle signal from choroid plexus artifact, whereas MK-6240's low background enables detection of early mesial temporal binding.
- Braak Stages III–IV (Limbic Stage): Tau pathology propagates via synaptically connected neural circuits into the hippocampus, amygdala, parahippocampal gyrus, and inferior temporal cortex. This stage typically coincides with the emergence of Mild Cognitive Impairment (MCI) and represents the critical therapeutic window where anti-amyloid monoclonal antibodies (such as Kisunla and Leqembi) deliver their greatest clinical benefit.
- Braak Stages V–VI (Isocortical / Neocortical Stage): Tau tangles invade the association neocortex (parietal, frontal, and occipital lobes), driving severe neuronal loss, widespread cortical metabolic failure, and frank Alzheimer's dementia. On MK-6240 PET visual reads, Braak V–VI manifests as intense, extensive cortical uptake easily differentiated from non-AD patterns.
How does MK-6240 compare with Eli Lilly's Tauvid (flortaucipir F-18)?
Eli Lilly's Tauvid (flortaucipir F-18 / AV-1451) was approved by the FDA in May 2020 as the first tau radiopharmaceutical indicated to estimate the density and distribution of aggregated tau neurofibrillary tangles in adult patients with cognitive impairment being evaluated for Alzheimer's disease.
While Tauvid demonstrated revolutionary proof-of-concept for tau imaging, first-generation tau radiotracers suffer from notable pharmacological liabilities—chiefly off-target binding to non-tau targets in normal brain tissues:
Comparative Radiochemistry: MK-6240 vs Incumbent Tau Tracers
┌───────────────────────┬────────────────────────────┬────────────────────────────┬─────────────────────────────┐
│ Diagnostic Metric │ MK-6240 (Florquinitau F-18)│ Tauvid (Flortaucipir F-18) │ PI-2620 (Investigational) │
├───────────────────────┼────────────────────────────┼────────────────────────────┼─────────────────────────────┤
│ Developer / Sponsor │ Lantheus (ex-Merck/Cerveau)│ Eli Lilly / Avid Radiopharm│ Life Molecular Imaging │
│ Target Binding Entity │ AD 3R/4R PHF-Tau Tangles │ AD 3R/4R PHF-Tau Tangles │ 3R/4R AD & 4R Tauopathies │
│ Off-Target Binding │ Described as minimal in │ Known off-target binding │ Minimal off-target binding │
│ │ preclinical/clinical │ (choroid plexus, MAO-B, │ reported │
│ │ characterizations │ basal ganglia, meninges) │ │
│ Choroid Plexus Spill │ Low — key design goal │ Prominent off-target spill │ Minimal off-target binding │
│ Basal Ganglia Binding │ Minimal non-specific uptake│ Substantial non-specific │ Clean basal ganglia kinetics│
│ Non-AD 4R Tau Binding │ Negligible (AD Specific) │ Minimal │ Moderate (Binds PSP/CBD) │
│ PDUFA / Approval Date │ August 13, 2026 (Target) │ Approved May 28, 2020 │ Late-Stage Development │
└───────────────────────┴────────────────────────────┴────────────────────────────┴─────────────────────────────┘
The Off-Target Binding Problem in Practice
In clinical PET interpretation, off-target binding in adjacent anatomical structures creates reading artifacts:
- Choroid Plexus "Spillover": Tauvid exhibits pronounced, non-specific binding in the choroid plexus (adjacent to the hippocampus and medial temporal lobe). Because the entorhinal cortex and hippocampus are the earliest anatomical sites of tau deposition (Braak Stages I–II), radiotracer activity spilling over from the choroid plexus into the hippocampus can confound early-stage Alzheimer's detection, creating reader uncertainty. Minimizing that spillover is a central design goal of second-generation tracers like MK-6240, which sponsors and early publications describe as showing minimal choroid plexus binding — final performance characteristics will come from the approved labeling if the NDA clears.
- Monoamine Oxidase B (MAO-B) Cross-Reactivity: Flortaucipir binds to MAO-B located in reactive astrocytes, the basal ganglia, and subcortical white matter, adding non-specific subcortical background. Second-generation tracers were engineered to avoid this cross-binding.
- Meningeal Uptake: First-generation tracers can show uptake in meningeal and skull structures, obscuring adjacent cortical ribbon activity — another contrast focus for second-generation chemistry.
What did the MK-6240 Phase 3 clinical trials show?
Lantheus's New Drug Application for MK-6240 is supported by a clinical program including two pivotal Phase 3 studies across the cognitive spectrum (cognitively unimpaired, mild cognitive impairment [MCI], and mild-to-moderate AD dementia). On April 30, 2025, Lantheus announced that MK-6240 met its co-primary endpoints — sensitivity and specificity — in both pivotal studies, and the company filed the NDA in the third quarter of 2025.
Pivotal Phase 3 Clinical Study Architecture
│
┌─────────────────────────────┴─────────────────────────────┐
│ │
[Neuropathology-Referenced Study] [Clinical Cohort Study]
• In vivo MK-6240 PET reads vs • Visual reads by independent
established truth standards for tau blinded readers across the
neuropathology cognitive spectrum
• Co-primary endpoints: • Co-primary endpoints:
sensitivity and specificity sensitivity and specificity
• Sponsor has not disclosed exact • Details expected in the
performance values in topline approved labeling at launch
communications
Three points matter for readers evaluating the evidence package:
- What has been disclosed: The co-primary endpoints (sensitivity and specificity for detecting tau NFT pathology) were met in both studies. That is the same endpoint construct the FDA used for Tauvid's 2020 approval, whose labeling reports performance against post-mortem neuropathology — the registrational precedent MK-6240 follows.
- What has not been disclosed: Exact sensitivity, specificity, reader-agreement, and cohort-size values have not been published in Lantheus's topline communications. Until the label or peer-reviewed publications appear, any precise performance numbers circulating in secondary sources should be treated with caution — including AI-generated summaries that invent plausible-looking values.
- The research footprint is already large: MK-6240 is used in nearly 100 active clinical trials, and the CLARiTI study leverages NACC infrastructure — meaning academic centers already have operational experience with the tracer before commercialization.
For broader analysis on Alzheimer's clinical trial trends, see our report on Alzheimer's disease clinical trials by the numbers.
Quantitative SUVR Metrics & Automated VOI Software Integration
In modern academic medical centers and clinical research trials, quantitative Standardized Uptake Value Ratio (SUVR) analysis provides objective numerical metrics of regional tau tangle burden — normalizing regional cortical uptake against a reference region (typically cerebellar cortex) that is relatively devoid of Alzheimer's tau pathology:
- Visual reads remain the labeled read-out for clinical use: trained readers score tracer uptake across tau-relevant cortical regions and classify the scan as positive or negative for the pattern of Alzheimer's-type tau pathology.
- Quantitative reads (regional and composite SUVR values) are the research standard — MK-6240 is already used this way across dozens of trials — and commercial workstations (e.g., MIM Software, Hermes Medical, GE HealthCare Cortex ID, Siemens Healthineers syngo.PET) can segment volumes of interest from co-registered MRI or low-dose CT to generate them.
- Cutpoint discipline: Specific SUVR thresholds are tracer-, protocol-, and reference-region-specific. No universally validated MK-6240 clinical cutpoints are published yet; adopting one at an institution requires validating against the labeled visual read rather than importing thresholds from other tracers or publications.
Radiation Dosimetry, Administration, and Patient Safety
Radiopharmaceutical safety and radiation exposure are critical operational factors for hospital radiology suites and nuclear pharmacies. For context from the approved incumbent: Tauvid's labeled recommended dose is 370 MBq (10 mCi) administered intravenously, with study participants having received 240-370 MBq. MK-6240 study protocols have used injected activities in the same diagnostic range typical of F-18 neuroimaging tracers. Published dosimetry work for MK-6240 exists in the peer-reviewed literature, but the operational numbers that matter — approved activity, organ dose, and effective dose — will be whatever the FDA-approved label specifies at launch. As with other diagnostic F-18 PET agents, no special premedication is expected; hydration and voiding guidance follows standard nuclear medicine practice.
Comprehensive Competitive Landscape Across Tau PET Radiotracers
To evaluate MK-6240's competitive moat against global pipeline candidates, we benchmark all major clinical-stage tau PET imaging agents:
Global Tau PET Radiopharmaceutical Development Landscape
┌───────────────────────┬──────────────┬──────────────┬──────────────┬───────────────────────────────┐
│ Radiotracer Molecule │ Originator │ Current Lead │ Radiochemical│ Clinical / Regulatory Status │
├───────────────────────┼──────────────┼──────────────┼──────────────┼───────────────────────────────┤
│ MK-6240 (Florquinitau)│ Merck & Co. │ Lantheus │ 18F-Labeled │ NDA Under Review (PDUFA Aug26)│
│ Flortaucipir (Tauvid) │ Avid / Lilly │ Eli Lilly │ 18F-Labeled │ FDA Approved (May 2020) │
│ PI-2620 │ Piramal/LMI │ Life Molec. │ 18F-Labeled │ Phase 3 Registrational Trials │
│ APN-1607 (Florzolotau)│ NIRS Japan │ APRINOIA Bio │ 18F-Labeled │ Phase 3 China / US Fast Track │
│ RO-948 │ Roche │ Roche / Gen. │ 18F-Labeled │ Phase 2/3 Biomarker Studies │
│ JNJ-64326067 │ Janssen │ Johnson & J. │ 18F-Labeled │ Discontinued / Early Phase │
└───────────────────────┴──────────────┴──────────────┴──────────────┴───────────────────────────────┘
MK-6240 is the clear front-runner among second-generation tau radiotracers, positioned to become the only commercial alternative to Tauvid in the United States with clean mesial temporal imaging kinetics.
Differential Diagnosis: Alzheimer's vs Non-AD Tauopathies
A critical clinical strength of MK-6240 is its biochemical specificity for Alzheimer's disease paired helical filament (PHF) tau compared to non-AD neurodegenerative tauopathies:
Tau Isoform Selectivity Across Neurodegenerative Diseases
┌───────────────────────────┬──────────────┬──────────────────┬────────────────────────────────────────┐
│ Clinical Disease Entity │ Tau Isoform │ Fibril Conformat │ MK-6240 PET Binding Characteristics │
├───────────────────────────┼──────────────┼──────────────────┼────────────────────────────────────────┤
│ Alzheimer's Disease (AD) │ 3R + 4R Tau │ Paired Helical │ High affinity; intensely positive │
│ Progressive Supranuclear P│ 4R Tau │ Straight / Ribbon│ Negligible binding; Clean negative scan│
│ Corticobasal Degen. (CBD) │ 4R Tau │ 4-Layer Fold │ Negligible binding; Clean negative scan│
│ Pick's Disease (FTLD-Tau) │ 3R Tau │ Narrow / Wide │ Low binding; Differentiates from AD │
│ Primary Age-Related Tauop │ 3R + 4R Tau │ Medial Temporal │ Confined strictly to entorhinal/hippoc.│
└───────────────────────────┴──────────────┴──────────────────┴────────────────────────────────────────┘
Because MK-6240 specifically targets the 3R/4R paired helical fold unique to Alzheimer's pathology, it enables clear differentiation between atypical Alzheimer's presentations (such as logopenic progressive aphasia or posterior cortical atrophy) and non-AD tauopathies (such as Richardson syndrome / PSP or behavioral variant FTD), preventing inappropriate and costly anti-amyloid antibody treatment in non-amyloid dementias.
Diagnostic Interplay: Blood Biomarkers vs Amyloid PET vs Tau PET
A critical decision facing health systems is how to structure a cost-effective diagnostic cascade for cognitive impairment:
Multi-Modality Alzheimer's Diagnostic Biomarker Comparison
┌───────────────────────────┬────────────────┬────────────────┬──────────────┬───────────────────────────────┐
│ Diagnostic Modality │ Clinical Role │ Typical Charge │ Invasiveness │ Turnaround / Availability │
│ │ │ Range (varies) │ │ │
├───────────────────────────┼────────────────┼────────────────┼──────────────┼───────────────────────────────┤
│ Plasma p-tau217 Assay │ Triage / Rule- │ Low hundreds │ Venipuncture │ Days (High-throughput lab) │
│ │ out │ of $ │ │ │
│ CSF Aβ42/40 & p-tau181 │ Confirmatory │ ~$1,000 range │ Lumbar Punct.│ Days (Invasive procedure) │
│ Amyloid-Beta PET (Amyvid) │ Plaque Status │ Several │ IV Radiopharm│ Same-day (Cyclotron dependent)│
│ │ │ thousand $ │ │ │
│ Tau PET (MK-6240 / Tauvid)│ Tangle Staging │ Several │ IV Radiopharm│ Same-day (Cyclotron dependent)│
│ │ │ thousand $ │ │ │
└───────────────────────────┴────────────────┴────────────────┴──────────────┴───────────────────────────────┘
Charge ranges are indicative list-price orders of magnitude; contracted and cash rates vary widely.
The 3-Tier Integrated Diagnostic Cascade
Rather than ordering PET scans on all memory-impaired patients, health systems are deploying a cost-effective 3-tier cascade:
- Tier 1 (Primary Care / Memory Clinic): Patient with cognitive complaints receives cognitive testing (MoCA) and a high-accuracy plasma p-tau217 blood test. If p-tau217 is negative (assay-specific cutoffs apply), Alzheimer's pathology is effectively ruled out (published negative predictive values above 90%), directing workup toward vascular dementia, normal pressure hydrocephalus, sleep apnea, or metabolic encephalopathy.
- Tier 2 (Amyloid Confirmation): If plasma p-tau217 is positive, the patient is referred to neurology for confirmatory amyloid assessment (Amyloid PET or CSF A$\beta 42/40$) to establish FDA label eligibility for anti-amyloid therapy.
- Tier 3 (Precision Tau Staging via MK-6240): For candidates considering donanemab (Kisunla) or complex presentations (atypical onset, early-onset AD, logopenic aphasia), an MK-6240 Tau PET scan determines the tau stage. Patients with intermediate tau burden are prioritized for aggressive therapy, while patients with extensive neocortical tau are counseled regarding reduced treatment responsiveness.
How does MK-6240 fit into the Leqembi, Kisunla, and p-tau217 diagnostic pathway?
The commercial and clinical imperative for next-generation tau PET tracers is directly propelled by the approval of disease-modifying anti-amyloid therapies and the rapid adoption of high-accuracy plasma blood biomarkers.
Modern 4-Step Alzheimer's Diagnostic & Treatment Pathway
│
┌──────────────────┬───────────────────┴───────────────────┬──────────────────┐
│ │ │ │
[Step 1: Clinical] [Step 2: Plasma p-tau217] [Step 3: PET Stage-Gate] [Step 4: Targeted mAb]
• MMSE / MoCA test • High-throughput blood test • Amyloid PET: Confirm • Leqembi: Amyloid(+)
• Subjective memory• %p-tau217 / total tau ratio • Tau PET (MK-6240): • Kisunla: Low/Medium Tau
complaint • Triages negative patients Stratify Low/Med/High Optimal responders
The Critical Role of Tau PET in Kisunla (Donanemab) Therapy
Eli Lilly's Kisunla (donanemab) was approved by the FDA in July 2024 with labeling directly shaped by its Phase 3 TRAILBLAZER-ALZ 2 trial design:
- In TRAILBLAZER-ALZ 2, participants were stratified by baseline tau PET into "Low/Medium Tau" (intermediate pathology) and "High Tau" cohorts.
- Patients in the Low/Medium tau group achieved dramatic cognitive slowing (35% slowing on the integrated Alzheimer's Disease Rating Scale [iADRS] at 76 weeks), whereas patients with advanced High Tau exhibited less slowing, demonstrating that anti-amyloid therapy is most effective before extensive isocortical tau tangles have destroyed cortical networks.
- While Kisunla's FDA label does not strictly mandate tau PET prior to prescribing, imaging with MK-6240 enables clinicians to identify optimal responders and avoid unnecessary, high-risk immunotherapy in patients who have already progressed past the point of clinical reversibility.
Synergy with Blood-Based Biomarkers (p-tau217)
The advent of blood-based biomarkers (such as ALZpath, Fujirebio, and C2N Diagnostics' plasma p-tau217 assays) has revolutionized early screening:
- Primary Care Triage: Plasma p-tau217 achieves $>90%$ negative predictive value for underlying Alzheimer's pathology, serving as a rapid, low-cost screening tool to rule out non-AD dementias.
- Confirmatory Imaging Gate: Because plasma p-tau217 measures soluble phosphorylated tau released into the circulation rather than insoluble fibrillar brain tangles, it cannot determine the anatomical distribution of neurofibrillary pathology. MK-6240 PET serves as the definitive spatial imaging stage-gate, mapping whether tau tangles remain confined to temporal lobes or have invaded frontal and parietal association cortices.
For related diagnostic regulatory dynamics, see our analysis on companion diagnostics FDA PMA expansions.
Reimbursement Economics & The Medicare Coverage Gap
Despite the clinical precision of tau PET radiopharmaceuticals, their commercial adoption is constrained by a fragmented, antiquated Medicare reimbursement architecture.
Medicare Radiopharmaceutical Payment Landscape
│
┌────────────────────────────────┼────────────────────────────────┐
│ │ │
[Hospital Outpatient (HOPPS)] [Local Coverage (MACs)] [NADAC Retail Pricing]
• Diagnostic radiopharmaceuticals• Retired Amyloid NCD (Oct 2023) • Zero Retail Claims
packaged into APC scan codes • No National Tau PET NCD • Radiotracers are provider-
• CY 2025 Separate Payment: • A/B MAC jurisdictions administered injectable
threshold: Drugs >$630/day local coverage determinations diagnostics, not retail Rx
Why Tau PET Tracers Are Absent from CMS NADAC
A query of the Centers for Medicare & Medicaid Services (CMS) National Average Drug Acquisition Cost (NADAC) pricing database returns zero entries for MK-6240, Tauvid, Amyvid, or any other PET radiotracer.
Unlike oral antiretrovirals or antihypertensives dispensed through retail pharmacies under Medicare Part D or commercial pharmacy benefits, PET radiopharmaceuticals are:
- Short-Lived Radioactive Diagnostic Agents: With physical half-lives of ~110 minutes ($^{18}\text{F}$), they cannot be inventoried or dispensed in standard retail pharmacy supply chains.
- Provider-Administered Diagnostics (Medicare Part B / OPPS): Billed under Healthcare Common Procedure Coding System (HCPCS) Level II codes — for the incumbent tau tracer, HCPCS A9601 (Flortaucipir F-18 injection, diagnostic, 1 millicurie) — administered directly within hospital outpatient radiology suites, freestanding imaging centers, or nuclear medicine clinics.
- Excluded from Retail Pharmacy Invoicing Surveys: Because these specialized radioactive compounds are delivered directly from nuclear radiopharmacies to institutional imaging centers on a per-patient unit-dose schedule, they bypass retail prescription survey methodologies altogether.
The CMS Coverage History: Amyloid vs Tau PET
The regulatory history of PET coverage by the Centers for Medicare & Medicaid Services reflects significant policy friction:
- The Amyloid PET Precedent (NCD 220.6.20): In 2013, CMS issued a National Coverage Determination (NCD 220.6.20) that severely restricted beta-amyloid PET coverage to clinical trials under Coverage with Evidence Development (CED). This restriction chilled amyloid imaging for a decade. On October 13, 2023, CMS formally retired NCD 220.6.20, returning amyloid PET coverage authority to local Medicare Administrative Contractors (MACs) such as Novitas, First Coast, Palmetto GBA, and Noridian.
- The Tau PET Vacuum: While amyloid PET now enjoys broad local MAC coverage when used to initiate Leqembi or Kisunla, CMS has never issued a National Coverage Determination for tau PET. As a result:
- Many commercial payers still classify tau PET as "investigational / experimental," requiring extensive peer-to-peer appeals and medical director reviews.
- Medicare coverage for Tauvid (and soon MK-6240) relies on variable Local Coverage Determinations (LCDs) or individual claim-by-claim medical necessity appeals processed by regional Medicare Administrative Contractors.
- When coverage is denied, patients face out-of-pocket facility and radiotracer charges commonly quoted in the several-thousand-dollar range per scan, creating significant financial toxicity.
The CY 2025 CMS OPPS Separate Payment Reform
A pivotal reimbursement catalyst landed in CMS's CY 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule (issued November 2024):
- Historically, CMS packaged the cost of diagnostic radiopharmaceuticals into nuclear-medicine APC payments — a structure that underpaid hospital imaging suites whenever the tracer's acquisition cost dwarfed the packaged amount.
- Effective CY 2025, CMS pays separately for diagnostic radiopharmaceuticals whose per-day cost exceeds $630, at a mean-unit-cost (MUC) rate derived from hospital claims, removing those costs from the packaged nuclear-medicine APC payments. The threshold updates annually by the Producer Price Index for Pharmaceutical Preparations beginning in CY 2026.
- Practical effect: a tau tracer whose per-dose cost exceeds the threshold no longer forces hospitals to absorb the gap between tracer acquisition cost and a packaged scan payment — a meaningful economic unlock for offering tau PET.
For insights on therapeutic radiopharmaceutical reimbursement structures, see our dossier on 177Lu-edotreotide radiopharmaceutical access.
Hospital Outpatient Coding & Prior Authorization Toolkit
To operationalize MK-6240 in clinical practice, imaging centers and nuclear medicine departments must utilize proper coding crosswalks:
Hospital Outpatient PET Billing Crosswalk
┌──────────────────────────────┬──────────────────┬───────────────────────────────────────────────────────────┐
│ Code Set │ Specific Code │ Description & Billing Usage │
├──────────────────────────────┼──────────────────┼───────────────────────────────────────────────────────────┤
│ CPT Technical / Professional │ CPT 78803 (+ │ Positron emission tomography (PET), metabolic brain │
│ │ PET/CT variants) │ imaging; PET/CT brain protocols use the concurrent-CT │
│ │ │ code family per payer policy. │
│ HCPCS Level II (Incumbent) │ HCPCS A9601 │ Flortaucipir F-18 injection, diagnostic, per millicurie. │
│ HCPCS Level II (MK-6240) │ To be assigned │ Expect a temporary pass-through C-code or permanent code │
│ │ │ at launch; monitor quarterly HCPCS updates. │
│ ICD-10 Diagnosis Codes │ G30.0 / G30.1 │ Alzheimer's disease with early / late onset. │
│ │ G31.84 │ Mild cognitive impairment, so stated. │
└──────────────────────────────┴──────────────────┴─────────────────────────────────────────────────────────────┘
Prior Authorization Appeal Strategy for Commercial Denials
When commercial payers deny tau PET coverage under "investigational" clauses, clinical documentation should emphasize three core arguments:
- Therapeutic Consequence: Documentation that tau staging directly determines candidacy for anti-amyloid monoclonal antibodies (donanemab / Kisunla) according to FDA-approved labeling.
- Diagnostic Specificity: Demonstrating that tau PET distinguishes AD from non-AD tauopathies (FTLD, PSP, CBD), preventing costly and inappropriate biologic immunotherapy.
- Safety Optimization: Preventing the administration of monoclonal antibodies associated with Amyloid-Related Imaging Abnormalities (ARIA-E and ARIA-H) in patients with advanced isocortical tau pathology where therapeutic benefit is blunted.
The Policy Horizon: What A National Tau PET NCD Would Take
Societies including the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the American College of Radiology (ACR), and the Alzheimer's Association have built the softer infrastructure for broader tau PET adoption — appropriate use criteria, clinical guidance, and diagnostic pathway frameworks. What does not yet exist is a formal CMS National Coverage Determination process for tau PET, and no NCA timeline is on the public record. The realistic path runs through:
- Evidence accumulation after approval: A second approved tracer plus growing use in anti-amyloid treatment selection builds the utilization and outcomes record that an NCA request would cite.
- Stakeholder-initiated request: An NCA can be opened by CMS itself or by an external formal request — historically how imaging NCDs (including the amyloid PET saga, CAG-00431) got started.
- Health-equity pressure: Without a national policy, tau PET access tracks local MAC policy and patient ability to self-pay — a disparity argument that becomes sharper as blood-based biomarker pathways standardize everything upstream of PET.
Until then, coverage advocacy happens payer by payer, LCD by LCD — the operating reality for imaging programs planning MK-6240 capacity.
Nuclear Pharmacy Supply Chain & Commercial Distribution Infrastructure
Commercializing an F-18 radiopharmaceutical requires a specialized just-in-time manufacturing and logistics network capable of delivering radioactive doses on tight schedules.
Nuclear Radiopharmacy Distribution Network
│
┌─────────────────────────────────┼─────────────────────────────────┐
│ │ │
[Regional Cyclotron Site] [Automated Synthesis & QC] [Direct-to-Clinic Delivery]
• Proton beam bombardment: • MK-6240 synthesis module • Unit-dose radioprotective pigs
18O(p,n)18F nuclear reaction • Radiochemical purity >95% • 3-4 hour transit radius
• 2-hour daily production • Endotoxin & sterile release • Synchronized patient injection
The U.S. Radiopharmacy Distribution Backbone
An F-18 tracer reaches clinics through an established U.S. infrastructure: regional cyclotron sites, automated radiosynthesis modules with cassette-based chemistry, rapid QC release, and unit-dose delivery — the same network that already moves Tauvid, amyloid tracers, and FDG daily:
- National radiopharmacy networks — operators such as Cardinal Health's nuclear pharmacy business, Siemens' PETNET Solutions, and Jubilant Radiopharma, alongside hospital-based cyclotrons — give a new tracer same-day reach into imaging suites without building distribution from scratch.
- Decay-compensated unit dosing: Doses are calibrated to deliver the prescribed activity at the scheduled administration time, accounting for the 109.8-minute half-life during transit.
- Scan-timing logistics: Static brain PET acquisition follows an uptake window after injection, synchronized across the dosing schedule — a workflow memory-care imaging programs already run for Tauvid.
The Lantheus Portfolio Context — and the Curium Wildcard
MK-6240's commercial story now includes a corporate plot twist. On August 3, 2026, Curium announced an agreement to acquire Lantheus in a deal reported at roughly $8 billion — a combination that would put MK-6240 inside the world's largest nuclear-medicine and radiopharmaceutical commercial platform (Curium's radiopharmacy and isotope supply infrastructure spans 70+ countries), pending closing and regulatory clearances. For imaging centers and payer teams, the practical read is that a second tau tracer would launch with arguably the strongest distribution muscle in nuclear medicine behind it.
Within the existing Lantheus portfolio, MK-6240 complements:
- Pylarify (18F-DCFPyL): The leading PSMA PET imaging agent for prostate cancer, generating annual revenue in the $850 million-plus range — the commercial anchor that built Lantheus's urology and nuclear medicine account base.
- Definity (perflutren): The echocardiography contrast franchise providing steady cash flow across cardiology and radiology suites.
- NAV-4694 (F-18 flutafuranol): Lantheus's investigational beta-amyloid PET tracer in Phase 3 development — meaning the company has been assembling both halves of the Alzheimer's imaging cascade (amyloid plus tau), positioning itself as the diagnostics partner for the anti-amyloid and anti-tau therapeutic pipeline.
Clinical Trial Evolution: Tau PET as a Development-Stage Biomarker
In early Alzheimer's clinical drug development, measuring changes on cognitive scales (e.g., CDR-SB, ADAS-Cog) requires large samples and 18-to-24-month endpoints. That is why tau PET has become a workhorse development tool: Lantheus notes that MK-6240 may help enable tau to serve as a surrogate endpoint for treatment efficacy — supporting earlier disease detection, patient staging, therapy selection, and monitoring in trials. Two economic mechanisms matter:
- Enrichment: Confirming tau pathology before randomization concentrates the trial population on patients most likely to progress and respond, reducing wasted screening slots — the same logic that made amyloid PET and plasma biomarkers standard in anti-amyloid trials.
- Target engagement and staging: Quantitative tau SUVR gives tau-directed programs (ASOs, aggregation inhibitors, anti-tau antibodies) a measurable pharmacodynamic signal far earlier than cognitive scales — one reason nearly 100 active trials already use the tracer.
Atypical Alzheimer's Presentations: Resolving Diagnostic Odysseys
While classical Alzheimer's disease presents with episodic anterograde amnesia, up to 15% of patients present with atypical focal cortical syndromes:
- Logopenic Variant Primary Progressive Aphasia (lvPPA): Characterized by impaired word retrieval and sentence repetition deficits. On MK-6240 PET, lvPPA patients demonstrate intense, asymmetric tau binding in the left posterior perisylvian and superior temporal cortex, distinguishing it from non-tau progressive non-fluent aphasia.
- Posterior Cortical Atrophy (PCA / Benson's Syndrome): Characterized by visual agnosia, Balint syndrome, and visuospatial disorientation. MK-6240 reveals dense tau accumulation localized to the bilateral peristriate and occipitoparietal cortices, confirming underlying Alzheimer's pathology despite completely preserved memory testing.
- Frontal Variant Alzheimer's Disease (fvAD): Characterized by early executive dysfunction, apathy, and behavioral disinhibition. MK-6240 differentiates fvAD (positive frontal and temporal tau) from behavioral variant frontotemporal dementia (bvFTD), which is tau PET negative.
What the CY 2025 OPPS Reform Means for Launch Economics
We deliberately avoid publishing a five-year Medicare utilization forecast here: credible numbers would require assumptions about MK-6240's approved label scope, pass-through payment rate, uptake against Tauvid, MAC-level coverage adoption, and the pace of blood-biomarker triage — none of which exists yet. What can be said concretely:
- Hospital payment math has improved structurally. Under the CY 2025 OPPS separate-payment policy, a diagnostic radiopharmaceutical above the $630/day threshold is paid separately at its hospital-claims-derived mean unit cost rather than being absorbed into a packaged scan payment. That converts tau PET from a potential loss-leader into a service line with defensible tracer economics.
- The binding constraint is coverage, not payment mechanics. Even with OPPS sorted, a scan that Medicare or commercial payers will not cover generates no volume. Watch three gates after approval: the assigned HCPCS code (and any pass-through status), early LCDs from the A/B MACs, and commercial medical-policy updates.
- Budget watchers should scale from the amyloid PET precedent. When coverage friction drops, dementia PET volume arrives gradually and protocolizes quickly behind blood-biomarker triage — plan capacity for staged growth rather than a step change.
Step-by-Step Radiology Suite Workflow: Patient Intake to Image Reconstruction
To maximize scanner throughput and minimize patient discomfort, nuclear medicine departments implement a standardized 5-step operational protocol:
Standardized Imaging Center Clinical Workflow
│
┌────────────────┬───────────────────┼───────────────────┬────────────────┐
│ │ │ │ │
[Step 1: Check-in] [Step 2: Radiopharm] [Step 3: Uptake] [Step 4: Scan] [Step 5: Process]
• Verify IV line • Dose calibration • 90-min resting in • 20-min static • Motion realign
• Confirm fasting/ • Label-dose slow IV quiet, low-light PET/CT scan • OSEM recon
medication status IV bolus inject room to relax • 4 x 5-min acq • SUVR auto-calc
- Step 1: Clinical Check-In & Pre-Scan Briefing (Minute 0): Verify patient identification, cognitive status, and obtain peripheral intravenous access (20- or 22-gauge catheter). No strict fasting is required, though patients are encouraged to void their bladder immediately prior to injection.
- Step 2: Dose Receipt & Intravenous Administration (Minute 15): The nuclear pharmacy unit dose of florquinitau F-18 is assayed in a dose calibrator to the prescribed activity (per the approved label at launch; Tauvid's labeled reference is 370 MBq / 10 mCi). The dose is administered as a slow intravenous push over 15 to 30 seconds, followed by a sterile saline flush.
- Step 3: Resting Uptake Window (Minutes 15–105): The patient rests comfortably in a quiet, dimly lit injection suite for 90 minutes. This incubation period allows unbound radiotracer to clear from blood pool and non-specific compartments, establishing optimal target-to-background signal contrast.
- Step 4: PET/CT Image Acquisition (Minutes 105–125): The patient is positioned supine on the PET/CT scanner with a head-holder restraint to minimize motion. A non-contrast low-dose head CT is acquired for attenuation correction, followed immediately by a 20-minute static PET emission scan acquired in 3D list mode (or 4 x 5-minute frames).
- Step 5: Motion Realignment & Reconstruction (Minutes 125–135): Dynamic frames are checked for patient head motion; frame-to-frame realignment is applied prior to 3D OSEM reconstruction (with point spread function and time-of-flight modeling). Automated DICOM push sends reconstructed volumes to PACS and quantitative SUVR analysis workstations.
International Dimensions to Watch
Lantheus has not announced specific EMA, PMDA, or NMPA filing timelines for MK-6240 in its public communications to date, so any dated international "filing strategy" you may read elsewhere should be treated with skepticism. Three international dynamics are nonetheless real and worth tracking:
- Europe's therapeutic gatekeeping shapes imaging demand. Anti-amyloid mAbs have faced a tougher European benefit-risk environment, which sharpens interest in biomarker-based patient selection — a pull factor for tau PET if and when European filings advance.
- Japan and China are advanced dementia-imaging markets with approved anti-amyloid therapies under national insurance and large diagnosed populations; second-generation tau tracers are in development there by other sponsors (e.g., APRINOIA's APN-1607/florzolotau), which could set the competitive backdrop for any MK-6240 ex-U.S. strategy.
- The Curium combination changes ex-U.S. math. Curium's international isotope production and radiopharmacy network is one of the largest outside the United States — if the Lantheus acquisition closes, MK-6240's international path gets structurally easier regardless of filing timing.
The Pipeline of Tau-Targeted Therapeutics: Beyond Monoclonal Antibodies
While current clinical practice focuses on using MK-6240 to stratify patients for anti-amyloid monoclonal antibodies, biopharmaceutical research is rapidly advancing direct tau-directed therapeutics:
Tau-Targeted Therapeutic Pipeline Mechanisms
│
┌────────────────────────────────┼────────────────────────────────┐
│ │ │
[Tau ASOs & Gene Silencing] [Anti-Tau Monoclonal Antibodies] [Tau Aggregation Inhibitors]
• BIIB080 (Biogen / Ionis) • Bepranemab (UCB) • LMTX / Hydromethylthionine
• Lowers total microtubule tau • Targets mid-domain tau • Inhibits paired helical
• Intrathecal dosing • Slows intercellular spread filament beta-sheet assembly
- Tau Antisense Oligonucleotides (ASOs): Biogen and Ionis's BIIB080 (MAPTRx) is an intrathecally administered ASO designed to degrade MAPT mRNA, reducing production of all tau isoforms. Early-phase data demonstrated dose-dependent reductions in cerebrospinal fluid total-tau and phosphorylated-tau — exactly the kind of program where tau PET provides the spatial, longitudinal read that CSF markers cannot.
- Next-Generation Anti-Tau Antibodies: Monoclonal antibodies targeting the N-terminal/mid-domain region of tau (e.g., UCB's bepranemab) aim to neutralize extracellular tau seeds and arrest trans-synaptic propagation; tau PET endpoints are the natural pharmacodynamic readouts for such programs.
- Small-Molecule Aggregation Inhibitors: Orally bioavailable molecules designed to prevent tau monomer hyperphosphorylation or disrupt beta-sheet assembly remain in early clinical development, with imaging-based target engagement as the development standard.
Health System Molecular Imaging Panel & P&T Decision Framework
To establish consistent institutional criteria for ordering and reviewing MK-6240 PET scans, health systems should adopt a 4-tiered molecular imaging review framework:
Health System Molecular Imaging Decision Architecture
┌──────────────────────────────┬──────────────────┬───────────────────────────────────────────────────────────┐
│ Decision Gate │ Clinical Criteria│ Actionable Institutional Protocol │
├──────────────────────────────┼──────────────────┼───────────────────────────────────────────────────────────┤
│ Tier 1: Biomarker Screening │ MoCA < 26 and │ Order plasma p-tau217 high-throughput blood assay; │
│ │ subjective memory│ if negative per assay cutoff, discharge from AD pathway. │
│ Tier 2: Amyloid Confirmation │ p-tau217 (+) │ Order confirmatory Amyloid PET or CSF Aβ42/40 ratio; │
│ │ │ confirm amyloid-positivity prior to biologic evaluation. │
│ Tier 3: MK-6240 Tau Staging │ Amyloid (+) and │ Perform baseline MK-6240 PET scan to differentiate │
│ │ considering mAb │ Low/Medium tau (ideal responder) vs High tau pathology. │
│ Tier 4: Longitudinal Tracking│ On active mAb or │ Optional 18-month follow-up scan to quantify suppression │
│ │ novel tau trial │ of neocortical tau tangle accumulation rate (SUVR delta). │
└──────────────────────────────┴──────────────────┴───────────────────────────────────────────────────────────┘
Clinical Practice Guidelines: NIA-AA Revised Diagnostic Criteria & AUC Integration
The clinical value of MK-6240 is reinforced by evolving consensus recommendations from leading neurodegenerative research societies:
NIA-AA Revised Biomarker (A/T/N) Framework
┌──────────────────────────────┬──────────────────┬───────────────────────────────────────────────────────────┐
│ Biomarker Profile │ Category T Read │ Typical Management Conversation │
├──────────────────────────────┼──────────────────┼───────────────────────────────────────────────────────────┤
│ A+/T- (asymptomatic or MCI) │ Medial temporal │ Monitor; trial-enrichment discussions; anti-amyloid │
│ │ tau confined │ candidacy if symptomatic per label. │
│ A+/T+ (intermediate spread) │ Limbic-stage tau │ The sweet spot for anti-amyloid mAbs per trial strat. │
│ A+/T++ (neocortical) │ Diffuse isocort. │ Diminishing anti-amyloid returns; ARIA risk-benefit │
│ │ │ weighs heavier; supportive/trial options. │
│ A- regardless of symptoms │ Non-AD workup │ Redirect to vascular/FTLD/LBD etiologies. │
└──────────────────────────────┴──────────────────┴───────────────────────────────────────────────────────────┘
- The NIA-AA Revised Criteria: The National Institute on Aging and Alzheimer's Association's revised diagnostic criteria define Alzheimer's biologically using biomarker profiles (A/T/N: Amyloid, Tau, Neurodegeneration), with numbered biological staging along the continuum. Tau PET is a definitive determinant of Category T, distinguishing localized medial temporal tau from diffuse neocortical tau.
- Appropriate Use Criteria (AUC): The SNMMI and Alzheimer's Association appropriate-use work recommends amyloid and tau PET in defined populations — including patients with persistent or progressive unexplained MCI, atypical or mixed presentations, and patients being considered for targeted monoclonal antibody immunotherapy.
Strategic Conclusion: Precision Staging for the Monoclonal Antibody Era
In summary, MK-6240 (florquinitau F-18) establishes a definitive technological leap in molecular neuroimaging. By eliminating the off-target choroid plexus and MAO-B binding artifacts that plagued first-generation tau tracers, Lantheus provides clinicians and clinical researchers with an uncompromised view of early-stage neurofibrillary tangle progression. As healthcare systems embrace plasma p-tau217 blood screening and disease-modifying monoclonal antibody therapy, MK-6240 will serve as the indispensable anatomical stage-gate, transforming subjective dementia care into an objective, biomarker-guided discipline.
Looking forward, the convergence of high-throughput blood-based screening with high-resolution tau PET imaging will dismantle historical bottlenecks in dementia clinical trials and accelerate the development of next-generation combination therapies. Health systems that invest in radiopharmaceutical cyclotron infrastructure, standardized image analysis software, and proactive payer coverage advocacy will be best positioned to lead the modern era of precision neurodegenerative medicine. Ultimately, the integration of quantitative tau PET into routine neurology workflows represents a vital milestone toward personalized Alzheimer's disease therapeutics, ensuring that the right patient receives the right disease-modifying intervention at the exact biological moment of maximum clinical benefit.
MK-6240 5-Pillar Strategic Scorecard
┌──────────────────────────────┬──────────────────┬─────────────────────────────────────────────────────────────┐
│ Strategic Dimension │ Evaluation Rating│ Key Analytical Findings & Market Drivers │
├──────────────────────────────┼──────────────────┼─────────────────────────────────────────────────────────────┤
│ 1. Diagnostic Specificity │ Strong (pending │ Designed for minimal choroid plexus/MAO-B off-target │
│ │ label values) │ binding vs first-gen Tauvid; co-primary endpoints met. │
│ 2. Clinical Trial Alignment │ Strong │ Directly mirrors Kisunla TRAILBLAZER-ALZ 2 tau staging; │
│ │ │ ideal confirmatory stage-gate after blood p-tau217 triage. │
│ 3. PDUFA & Approval Odds │ Favorable │ Fast Track status; PDUFA date August 13, 2026; decision │
│ │ │ pending as of this writing. │
│ 4. Supply Chain Logistics │ High Scalability │ Established US radiopharmacy networks (plus the Curium │
│ │ │ combination) support same-day unit-dose distribution. │
│ 5. Reimbursement Hurdles │ Challenging │ Absence of National Coverage Determination (NCD) for tau PET│
│ │ │ requires ongoing local MAC and commercial payer advocacy. │
└──────────────────────────────┴──────────────────┴─────────────────────────────────────────────────────────────┘
Frequently Asked Questions
What is MK-6240 and who is developing it?
MK-6240 (florquinitau F-18) is an investigational second-generation positron emission tomography (PET) imaging agent that binds with high affinity to hyperphosphorylated tau neurofibrillary tangles in the human brain. Originally discovered by Merck & Co., it was developed by Cerveau Technologies and is being commercialized by Lantheus Holdings.
What is the FDA PDUFA date for MK-6240?
The FDA accepted the New Drug Application for MK-6240 (announced October 28, 2025) with Fast Track designation, and set a Prescription Drug User Fee Act (PDUFA) target action date of August 13, 2026. No FDA decision had been publicly announced as of this article's last update.
How is MK-6240 different from Eli Lilly's Tauvid (flortaucipir F-18)?
While both tracers bind paired helical filament tau in Alzheimer's disease, MK-6240 exhibits substantially lower off-target binding in the choroid plexus, basal ganglia, and meninges, and does not cross-bind to monoamine oxidase B (MAO-B). This significantly reduces false-positive reads in the hippocampus and medial temporal lobe, allowing clearer visualization of early-stage Braak I–II tau pathology.
Is tau PET required before prescribing Leqembi or Kisunla?
Tau PET is not strictly required by the FDA label for Leqembi (lecanemab), which only requires confirmation of amyloid-beta pathology. For Kisunla (donanemab), while the Phase 3 trial stratified patients by tau burden (Low/Medium vs High), the final FDA label allows prescribing based on confirmed amyloid pathology; however, clinical guidelines increasingly recommend tau PET to identify optimal treatment responders and guide discontinuation timing.
Why is tau PET not covered by a National Coverage Determination from CMS?
CMS retired the beta-amyloid PET National Coverage Determination (NCD 220.6.20) in October 2023, delegating coverage decisions to local Medicare Administrative Contractors (MACs). However, CMS has never created a national NCD specifically for tau PET. Coverage currently varies by local MAC and commercial plan, though the CY 2025 OPPS separate-payment policy for diagnostic radiopharmaceuticals (per-day cost above $630) significantly improves hospital outpatient economics.
What is the radiation dose associated with an MK-6240 PET scan?
The total effective radiation dose from an MK-6240 injection will be specified in the approved labeling at launch; diagnostic F-18 PET tracers typically produce effective doses in the same order as other nuclear-medicine diagnostic studies, and the approved label — not secondary summaries — is the figure to use for consent forms and protocol documents.
Can MK-6240 PET detect non-Alzheimer's tauopathies like PSP or Pick's disease?
No. MK-6240 is selective for the paired helical filament conformation of tau consisting of both 3-repeat (3R) and 4-repeat (4R) isoforms found in Alzheimer's disease. It exhibits minimal binding to straight tau filaments found in 4R tauopathies (Progressive Supranuclear Palsy and Corticobasal Degeneration) or 3R tauopathies (Pick's disease), making it an effective negative discriminator.
How does MK-6240 PET compare with cerebrospinal fluid (CSF) p-tau assays?
While CSF assays (such as Elecsys p-tau181 or Lumipulse p-tau217) provide sensitive global measures of cerebral tau pathophysiology, they cannot determine the regional anatomical distribution or neocortical extent of neurofibrillary tangles. MK-6240 PET provides spatial, anatomical Braak staging across specific cortical subregions, which is essential for determining whether tau pathology remains confined to the limbic system or has invaded frontal and parietal association networks.
What are the operational storage and transport requirements for florquinitau F-18?
Due to the 109.8-minute physical half-life of Fluorine-18, MK-6240 is formulated as an isotonic unit-dose solution supplied in lead- or tungsten-shielded radioprotective containers ("pigs"). Doses are transported by specialized hazardous-materials couriers directly to hospital nuclear medicine suites, with scheduled calibration times calculated to ensure exact patient radioactivity delivery at the time of administration.
What patient preparation instructions are required prior to undergoing an MK-6240 scan?
Patients do not need to fast or withhold standard medications prior to an MK-6240 scan. However, clinical staff advise patients to arrive well hydrated and void their bladder both immediately before tracer injection and prior to scanner table positioning to minimize pelvic radiation absorption and maximize imaging comfort during the 20-minute scan acquisition.
How will MK-6240 impact clinical decision-making for anti-amyloid treatment discontinuation?
In clinical trials such as TRAILBLAZER-ALZ 2, patients who achieved amyloid clearance were transitioned off active monoclonal antibody therapy. Incorporating baseline and follow-up MK-6240 PET scans provides quantitative evidence regarding whether downstream tau tangle spread has stabilized, offering neurologists an objective biological biomarker to support treatment pauses, drug holidays, or maintenance dosing schedules.
How should clinical documentation be structured to prevent insurance denials for tau PET?
Ordering physicians should document the patient's objective cognitive scores (MoCA/MMSE), results of confirmatory amyloid testing or elevated blood p-tau217, the specific therapeutic rationale (e.g., evaluating candidacy for FDA-approved monoclonal antibody therapy), and the absence of confounding neurological conditions. Explicitly linking the scan results to actionable treatment decision-making is the single most effective way to overturn commercial payer investigational exclusions.
Sources
- Lantheus Holdings, Inc. Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer's Disease (NDA acceptance; Fast Track; PDUFA August 13, 2026). Press Release, October 28, 2025. Available at: lantheusholdings.gcs-web.com.
- Lantheus Holdings, Inc. Lantheus Announces Alzheimer's Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies (sensitivity and specificity). Press Release, April 30, 2025. Available at: lantheusholdings.gcs-web.com.
- AuntMinnie. FDA accepts NDA for Lantheus' PET tracer (MK-6240 / florquinitau F-18; Enigma Biomedical partnership). October 28, 2025. Available at: auntminnie.com.
- AuntMinnie. Curium to acquire Lantheus in $8 billion deal. August 3, 2026. Available at: auntminnie.com.
- Eli Lilly and Company. Tauvid (Flortaucipir F-18 Injection) Prescribing Information and FDA Approval History (NDA 212123; approved May 28, 2020; recommended dose 370 MBq / 10 mCi). Available at: accessdata.fda.gov.
- Centers for Medicare & Medicaid Services (CMS). Decision Memo for Beta-Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG-00431R) — Retirement of NCD 220.6.20. Published October 13, 2023. Available at: cms.gov.
- Centers for Medicare & Medicaid Services (CMS). CY 2025 Medicare Hospital Outpatient Prospective Payment System Final Rule Fact Sheet (separate payment for diagnostic radiopharmaceuticals with per-day cost above $630, at mean unit cost). Available at: cms.gov.
- Centers for Medicare & Medicaid Services (CMS). National Average Drug Acquisition Cost (NADAC) Pricing Database, 2026-07-24 Snapshot (no retail rows for PET tracers or anti-amyloid mAbs). Available at: data.medicaid.gov.
- NeurologyLive. FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer's (nearly 100 active trials; ~30 tau- and ~40 amyloid-targeting DMTs in development; CLARiTI/NACC). Available at: neurologylive.com.
- Sims JR, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA, 2023; 330(6):512-527. Available at: jamanetwork.com.
- van Dyck CH, et al. Lecanemab in Early Alzheimer's Disease (Clarity AD). New England Journal of Medicine, 2023; 388(1):9-21. Available at: nejm.org.
- Lohith TG, Bennacef I, Vandenberghe R, et al. First-in-human brain imaging of Alzheimer dementia patients and elderly controls with 18F-MK-6240, a PET tracer targeting neurofibrillary tangles. Journal of Nuclear Medicine, 2019; 60(1):107-114. Available at: jnm.snmjournals.org.
